Acorda Therapeutics - Stock Price History | ACOR

Historical daily share price chart and data for Acorda Therapeutics since 2021 adjusted for splits. The latest closing stock price for Acorda Therapeutics as of September 24, 2021 is 4.74.
  • The all-time high Acorda Therapeutics stock closing price was 266.95 on January 26, 2015.
  • The Acorda Therapeutics 52-week high stock price is 9.84, which is 107.6% above the current share price.
  • The Acorda Therapeutics 52-week low stock price is 2.89, which is 39% below the current share price.
  • The average Acorda Therapeutics stock price for the last 52 weeks is 4.79.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Acorda Therapeutics Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 5.8431 11.7576 14.8770 2.6995 4.1398 -66.17%
2019 47.2616 97.3005 104.7990 9.1182 12.2376 -86.91%
2018 141.5511 135.8728 195.5609 77.6245 93.4613 -27.37%
2017 129.1242 116.9766 180.8638 82.7834 128.6743 14.10%
2016 159.1163 253.4493 253.4493 98.6803 112.7774 -56.05%
2015 208.4176 243.0114 266.9466 154.6491 256.6287 4.67%
2014 201.9847 173.7253 246.3707 167.2466 245.1710 39.97%
2013 198.4431 150.9898 242.5915 150.9898 175.1650 17.46%
2012 148.1930 146.7307 165.6869 129.6941 149.1302 4.28%
2011 150.3454 161.9676 198.4403 112.2376 143.0114 -12.55%
2010 189.5533 152.6695 238.1524 150.2699 163.5273 8.17%
2009 140.7639 122.6155 169.1062 100.4199 151.1698 22.87%
2008 140.5590 130.4139 208.1584 92.3815 123.0354 -6.60%
2007 118.0460 93.6413 153.3893 92.0816 131.7337 38.64%
2006 47.2491 40.3119 120.5159 13.3173 95.0210 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.050B $0.153B
Acorda Therapeutics, Inc. is a biotechnology company developing and commercializing neurology therapies for Parkinson's disease, migraine and multiple sclerosis. Acorda has a pipeline of novel neurological therapies addressing a range of disorders, including Parkinson's disease and multiple sclerosis. Acorda markets three FDA-approved therapies, including AMPYRA? (dalfampridine) Extended Release Tablets, 10 mg.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $134.727B 8.97
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.500B 21.17
Biohaven Pharmaceutical Holding (BHVN) United States $8.865B 0.00
Emergent Biosolutions (EBS) United States $2.891B 6.97
Arcus Biosciences (RCUS) United States $2.641B 0.00
Myovant Sciences (MYOV) United Kingdom $2.145B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.998B 0.00
Zymeworks (ZYME) Canada $1.380B 0.00
Ambrx Biopharma (AMAM) United States $0.521B 0.00
SQZ Biotechnologies (SQZ) United States $0.427B 0.00
Enzo Biochem (ENZ) United States $0.175B 51.71